FDA Approval of<sup>18</sup>F-Flurpiridaz for PET: Stepping into a New Era of Myocardial Perfusion Imaging?

20257 citationseditorialbronze Open Access

Authors

Thomas H. Schindler

Timothy M. Bateman · Society of Nuclear Medicine and Molecular Imaging

Daniel S. Berman · Society of Nuclear Medicine and Molecular Imaging

Panithaya Chareonthaitawee · American Nuclear Society

Lorraine E. De Blanche

Vasken Dilsizian · American Nuclear Society

Sharmila Dorbala · Society of Nuclear Medicine and Molecular Imaging

Abstract

Recently, the U.S. Food and Drug Administration (FDA) approved 18F-labeled flurpiridaz as another PET myocardial perfusion imaging (MPI) radiotracer for clinical use in adult patients with known or suspected coronary artery disease (CAD). This decision was based on recent results of a second phase 3

Topics & Keywords

Cardiac Imaging and Diagnostics Medical Imaging Techniques and Applications Radiopharmaceutical Chemistry and Applications

Publication Details

Published in: Journal of Nuclear Medicine

Volume 66, Issue 6, pp. 862-864

DOI: 10.2967/jnumed.124.269154

Field-Weighted Citation Impact: 9.76

Command Palette

FDA Approval of<sup>18</sup>F-Flurpiridaz for PET: Stepping into a New Era of Myocardial Perfusion Imaging?

Authors

Abstract

Topics & Keywords

Publication Details